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The first cause of tooth loss in developed countries is 
periodontitis and mostly occurs in people over 40 years old.1 
Periodontal disease is an inflammatory infection, which has 
been observed in the preserving tissues of teeth in sensitive 
individuals to this disease. The gingival disease affected by 
plaque (gingivitis) is reversible if it is limited to the gingiva 
and is different from the periodontal disease, which is 
chronic and aggressive. Chronic periodontitis is irreversible 
and if left untreated can result in tooth loss. According to the 
changing nature of the disease criteria, the prevalence of per- 
iodontitis is different in every study. The third international 
meeting of health and nutrition (NHANES III) has reported 
the prevalence of periodontitis in the moderate and severe 
situations is about 14% of the population older than 26 years 
in USA.2 
Periodontitis is a multifactorial disease initiated by 
microbial plaque, but its spread and severity depend on the 
environmental factors, acquired diseases, and individual’s 
genetic predisposition. Loosening of teeth, destruction of pre- 
serving tissue, and its loss is the most important factor of this 
disease.3 The initial inflammatory response to the dental 
microbial plaque is leaded by polymorphonuclear neutronphils 
(PMN), which will detect the microorganisms of microbial 
plaque through their surface receptors. The activation of these 
receptors by the pathogen results in their phagocytosis and the 
secretion of pro-inflammatory cytokines such as IL-B, IL-6, 
IL12, and TNF-α, which cause periodontal tissue destruction. 
In the inflamed gingival, high levels of the   tissue-degrading 
 
enzymes such as matrix metalloproteinases (MMPs) are 
found. MMPs cause the destruction of the extracellular matrix; 
including collagen, gelatin, and elastin, which will eventually 
result in periodontal tissue destruction and the loss of alveolar 
bone. When the inflammatory products reach the bone 
surface, bone destruction might start representing in this way 
the transition from gingivitis to periodontitis.4 
Periodontitis with local inflammation that is made 
through the release of pro-inflammatory cytokines leads to 
increasing of systematic inflammation5 and the accumulation 
of inflammatory mediators increase inflammatory activity in 
atherosclerotic plaque.6,7 
Atorvastatin is a statin drug class that had a revolutionary 
impact on the treatment of high cholesterol through the inhibi- 
tion of 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA). 
The inhibitory impact of HMG-CoA reductase is usually 
attributed to their ability in the reduction of the synthesis of 
endogenous cells. Statins are responsible for a variety of bio- 
chemical changes including reduction of the cholesterol 
accumulation in macrophages, an increase of intracellular 
synthesis of NO, reduction of the inflammatory process and 
increase of the stability of atherosclerotic plaques.8 Atorvastatin 
is also used to suppress metalloproteinase.9,10 Statins reduce the 
production of mevalonate, geranyl pyrophosphate, and farnesyl 
pyrophosphate and the next production in a way to make 
cholesterol. Therefore, statins could prevent the inflammatory 
process by inhibiting the pathway of cholesterol and the 
interference with the performance of RAS family of proteins.11 
Statins are also the strong stimulants of protein forming bone 
morphology protein (BMP-2), which is the main inducer of the 
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potential bone formation. Simvastatin, Myostatin, and Ator- 
vastatin induce the transcription of the BMP-2.12 
Numerous laboratory animal species including non- 
human primates, dogs, rats, guinea pigs, Syrian hamsters, 
ferrets, and rice rats have been used in the pathophysiology 
study or preventive treatment tests for periodontitis control or 
its improvements.13 In a study of Chang et al.,14 Atorvastatin 
significantly reduced bone loss and the amount of IL-6 in 
serum and helped the formation of bone. In the study of 
Subramanian et al.,5 the reduction of periodontitis and 
inflammation rate by Atorvastatin was stated as a finding. de 
Araújo Júnior et al.8 mentioned the anti-inflammatory proper- 
ties of oral Atorvastatin that is appeared by the reduction of 
cytokine expression and oxidative stress in the experimental 
periodontitis. Balli et al.12 had an experiment on 100 rats in 
different periodontitis phases and found systemic and topical 
Atorvastatin effective in the first phase of periodontitis and 
suggested that it is useful in periodontal treatment as an 
implant substance. 
In the cited studies, local effects of Atorvastatin on the 
inflammation and loss of alveolar bone in periodontitis has 
not been studied enough and no comparisons have been done 
from the different aspect of the effectiveness of local and sys- 
temic methods and there is also a need for expanded research 
to verify the effect of this essential drug. 
The aim of this study is to evaluate the effect of local and 
systemic Atorvastatin in the treatment of periodontitis by 
measuring inflammation by malondialdehyde (MDA) and 
superoxide dismutase (SOD) tests from gingival samples and 
histopathology analysis of slices of alveolar bone of the rat’s 





After statistical consultation, 46 rats from male Sprague Dawley 
race (to remove the effect of sex hormones) with the weight of 
180–200 g and with the age of 8–12 weeks were used in this study. 
Preparation of Solution 
After the experiments, propylene glycol and phosphate buffer 
solution were chosen as solvents. 
Periodontitis induction 
After anesthesia through subcutaneous injection, animal 
ketamine hydrochloride 10% compound with a dose of 70 mg/kg 
and zylazine 2% with a dose of  10  mg/kg,  ligature  thread (3-
0 ETHIBOND EXCEL polyester green-coated braided non-
absorbable) was tied around the second molar teeth on the left 
side of maxillary and tied in the palatal area. 
Grouping 
The rats were randomly divided into six groups of eight in each 
and a control group without ligature thread was considered as 
a control to show the impact of experimental periodontitis. 
 
First group 
Oral Atorvastatin was administered by gavage method 
after the periodontitis induction for 10 days, 1 ml each day of 
oral solution and sacrificed on the 11th day. 
Second Group 
Like the first group, only the pharmaceutical solution was 
administered without pharmaceutical substance. 
 
Third Group 
After periodontitis induction for 10 days, 0.05 ml each 
day injection Atorvastatin was injected in buccal alveolar on 
the left side of maxillary second molar at the base of the teeth 




Like the previous group and only the injection solution 
without pharmaceutical substance was injected. 
 
Fifth Group 
After periodontitis induction for 10 days without any phar- 
maceutical substance. This group was sacrificed on the 11th day. 
 
Sixth Group 
This group was sacrificed with other groups without any 
kind of periodontitis induction and any pharmaceutical sub- 
stance. 
All animals were kept in the standard situation (12 h the 
day length and 12 hours the night length, at 22°C ambient 
temperature with access to food and water) in the groups. 
All groups were transferred to the container of saturated 
ether for sacrificing and then they were sacrificed and 
beheaded and the soft tissue was separated from maxillary by 
scalpel and then put in 10% formalin with three times the 
volume of the sample for 3 days. 
Superoxide Dismutase Test 
Activity was measured by Misre and Fridorich process. This 
method is based on the autoxidation inhibition of adrenaline 
to adrenochrome SOD pH = 10.2. Adrenochrome absorbs 
light in 480 nm. Landa buffer solution 550 is prepared by 0.3 
mol/l of NaHCO
3
NaCO with pH = 10.2 and 400 Landa of 
0.075 EDTA and 750 Landa of 1.30 serum diluted sample. A 
control tube containing distilled water instead of the sample  
is also prepared. After a minute of adding 500 Landa of 1.8 
nmol/l adrenaline, acid chloride solution (HCL) with pH = 2 
is added to the control tube and test sample and the 280 nm 
absorption is read. Percentage of inhibition of adrenaline 
autoxidation against different standard SOD density was 
drawn. Using the above information and considering the 
amount of produced enzyme that perform 50% inhibition of 
adrenaline auto oxidation,15 the result of SOD activity has 
been reported based on unit/mg protein or    unit/ml. 
Malondialdehyde Test 
Malondialdehyde is an indirect index of lipid peroxidation 
and colorimetric is done based on the inactive TBARS acid. 
Approximately, 0.5 mm of serum is added to the 2 mm TBA 
reagent which includes 0.375% of TBA, 15% trichloroacetic 
acid and 0.25 mol of hydrochloric acid. The solution is boiled 
for 15 min and then cooled and centrifuged in 170 g for      
15 min in 4°C. 
Absorption of floating solution on the surface is measured 
in 523 nm and obtained in TBARS density by the calculation 
of TEP standard. The results are reported based on the nmol/ 
mg of serum protein.8 
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Slide Preparation Steps 
 
Declassifying 
After taking samples out of formalin, maxilla is put in the 
10% nitric acid for 72 h. 
After removing the thread around the teeth, areas of 
premolar and molar teeth on the left were cut in the direction 
of back to front and parallel with the midsagittal axis. Each 
part is put in a dry capsule and in formalin for 12 h and then 
passed through autotechnicon machine containing the dishes 
of 70%, 80%, 96% and 100% formalin alcohol, xylene, and par- 
affin, respectively. After the above steps, molding is done with 
thin 5-micron slices of paraffin from the mid area of samples. 
To destroy, paraffin is put in the oven with 80°C for 45 min and 
then staining was done. 
H&E Staining 
To stain hematoxylin and eosin (H&E), samples were passed 
through three containers of xylelfor 3–10 min to remove the 
paraffin. In the next step, they were passed through ethylic 
alcohol 70%, 80%, and 96%, respectively, three times and each 
time for 1 min and put in hematoxylin after washing with 
water completely for 5 min and washed again to remove the 
extra stain. By adding 100 cc of 70% alcohol to 1 cc of 1% 
chloric acid, alcohol acid was obtained and it was entered to 
alcohol acid for 5 s, the samples then were entered to 2% 
ammonia water to fix the stain and then put in eosin for 1 min 
and after a complete wash they were taken to the container of 
96 and 100% alcohol and three times to the xylelcontainer. 
Histopathologic Study 
Provided H&E slides were marked based on giving random 
numbers to the samples in each group and investigated by 
light microscope carefully and different magnifications in a 
blind way. 
Investigation of Inflammation and Alveolar Bone 
Loss 
The area between first and second molar teeth was studied 
with 40× magnification and parameters, such as infiltration of 
inflammatory cells; alveolar bone integrity and cementum 
were evaluated and graded as follows: 
Score 0: Lack and little amount of infiltration of inflamma- 
tory cells, which are limited to the marginal gingiva and 
alveolar bone and cementum were preserved. 
Score 1: Average infiltration of inflammatory cells (infiltra- 
tion spreads through the gingiva), little loss of alveolar bone 
and cementum. 
Score 2: Severe infiltration of inflammatory cells (outspread 
in the gingiva and PDL) and an average loss of alveolar bone 
and partial destruction of cementum. 
Score 3: Severe infiltration of inflammatory cells,  complete 
destruction of alveolar cells, and severe destruction of cementum. 
Statistical Analysis 
Statistical analysis was done for the analysis of the results of 
MDA and SOD tests by using one-way ANOVA with Duncan 
post-hoc test. 
Statistical analysis was in a non-parametric way and with 
Kruskal–Wallis test to compare between groups and Mann– 
Whitney test was applied pairwise in different groups for grading 
of histopathological tests. 
Kruskal–Wallis test was done with P-value < 0.05 care 
which indicates a significant statistical difference of grading 
variables of destruction (scores) and the number of the oste- 
oclasts. This means that there is a difference among groups 
that this significant difference can be created by one differ- 





In this test, the results were reported based on the serum 
amount of SOD with serum unit/mol unit. As it is observed, 
there is no significant difference among different groups, the 
maximum amount of SOD speed was reported in oral Ator- 
vastatin (49.94), and the minimum amount was in an oral 
solvent (44.68) (Table 1). 
MDA Test 
In this test, the result is obtained based on the amount of MDA 
serum with nmol/mg unit. As it is observed, there is a signifi- 
cant difference (P-value ≤ 0.05) between the control group, 
injection Atorvastatin, oral Atorvastatin with other groups 
and the minimum amount was seen in the control group 
(1.22), and the maximum amount was in tied tread group 
(2.36) (Table 2). 
Histopathologic Evaluation 
With Mann–Whitney test, there was a significant difference 
between the control group with the median of (0) and tied 
thread with the median of (3) (P-value = 0.000). 
There was also a significant difference between injected 
Atorvastatin with the tied thread group (P = 0.001) and 
injected solvent (P-value = 0.004). 
As it canbe seen in Table 3, the results of injected Atorvastatin 
were better than oral Atorvastatin, but there was no significant 
difference between these two groups (P-value = 0.228). 
Table 1. Mean amount of SOD (unit/ml) in the study groups 
Group Mean Std. deviation 
Control 49.23 11.88 
Tied thread 48.86 10.93 
Oral atorvastatin 49.94 11.27 
Oral solvent 44.68 12.42 
Injected  atorvastatin 43.79 11.31 
Injected solvent 46.15 10.98 
 
Table 2. Mean amount of MDA (nmol/mg) in the study groups 
Group Mean Std. deviation 
Control 1.22 0.49 
Tied thread 2.37 0.71 
Oral atorvastatin 1.45 0.52 
Oral solvent 2.18 0.64 
Injected  atorvastatin 1.48 0.61 
Injected solvent 2.10 0.77 
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Table 3. Median distribution of histopathology score in the 
studied groups 
Group Number Median Std. deviation 
Control 8 0 0 
Tied thread 7 3 0.57735 
Oral atorvastatin 6 2 0.63246 
Oral solvent 6 3 0.40825 
Injected  atorvastatin 8 1.5 0.53452 
Injected solvent 7 3 0.48795 
 
The maximum number of osteoclasts was counted in tied 
thread group and the minimum number was in the control 
group. The number of osteoclasts in Atorvastatin group was 
less than tied thread group. 
The maximum amount of mixed inflammation was 
observed in tied thread group and the minimum amount was 
in injected Atorvastatin group. The maximum destruction of 
collagen was seen in the tied thread group and the minimum 
amount was in the control group. 
The maximum amount of maxillary bone destruction in 
the studied groups was seen in the tied thread group and the 




The present study has shown that both systemic and topical 
Atorvastatin treatment had significant inhibitory effects on 
inflammatory changes and alveolar bone resorption following 
an experimental periodontic treatment in mice. It was also 
found that Atorvastatin is capable to inhibit inflammation and 
bone loss associated with collagen degradation. 
An increase in oxidants and free radicals produced during 
inflammation is one of the mechanisms of tissue pathogenesis. 
It seems that increased serum levels of oxidants and decreased 
antioxidant enzymes promote inflammation and alveolar bone 
loss on cascade pathway by activation of proinflammatory 
cytokines, such as IL-6, IL-1, and TNF-α subsequently acti- 




Fig 1. Control group (H&E 40×) normal without periodontitis. 









Fig 2. Ligature threaded (H&E 40×) periodontitis group. 




Fig 3. Injected Atorvastatin group (score 1) (H&E 40×) little loss 
of alveolar bone and inflammation. 
 
 
Fig 4. Oral Atorvastatin group (score 2) (H&E 40×) severe infiltra- 
tion of inflammatory cells in gingival, PDL and alveolar bone. 
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Our result is consistent with other studies15–17 demon- 
strated that the effectiveness of the oral administration of 
Atorvastatin to prevent the alveolar bone resorption and 
cartilage destruction in the experimental periodontitis. 
Several authors have reported the successful use of 
Atorvastatin on periodontitis, by reducing tooth loss in 
patients with the chronic periodontitis,15 exhibiting the fewer 
signs of inflammatory injury.16 
In a study conducted by Bertl et al.16 a significant clin- 
ical and radiographic improvements are  obtained  after local, 
but not systemic statin use as an adjunct to scaling root 
planning in deep pockets in patients with chronic 
periodontitis. 
In another study, Sinjab et al.17 found that adjunctive use 
of locally delivered statins to mechanical scaling and root plan- 
ning is beneficial as it increases bone fill percentage. Improved 
inflammatory and bleeding control as well as probing depth 
reduction and clinical attachment level gain are possible fol- 
lowing administration of these drugs in treating patients with 
chronic periodontitis. 
In a study by de Araújo Júnior et al.8 it has been reported 
that 10 mg/kg of Atorvastatin can reduce alveolar bone loss, 
proinflammatory cytokines, oxidative stress, and expression of 
extracellular matrix proteins, as well as RANK/RANKL while 
increases osteoprotegerin (OPG) in the periodontal disease in 
male Wistar albino rats. 
In a study that was conducted by Chang et al.14, he 
reported that Atorvastatin reduced the bone resorption 
parameters, including the Ca/Cr and P/Cr in 24 hours urine 
and the serum level of IL-6 can decrease the bone resorption 
and increase the bone formation. The results of this study have 
been consistent with the present study results. 
In another study performed by Bali et al.12 on 100 rats, it 
was for the first time that a study compared the effect of the 
local versus systemic Atorvastatin administration. They 
reported a positive effect of both administration paths on the 
periodontium by histomorphometry and immunohistochem- 
istry tests. 
The results of this study were in agreement with previous 
studies reporting the positive effects of Atorvastatin on perio- 
dontitis and have showed that Atorvastatin can prevent the 
alveolar bone loss at the macroscopic level in experimental 
periodontitis.11,18 
Other studies showed a significant reduction of alveolar 
bone resorption and the collagen degradation in the experi- 
mental periodontitis after Atorvastatin administration.21 
Based on the study conducted by Estanislau et al.21 statins 
reduce bone resorption by inhibiting osteoclast forma tion. 
Bone formation is related to the increased gene expression of 
bone morphogenetic protein in osteoblasts. 
Previous studies have shown that statins reduce the 
number of monocytes as precursors of Osteoclast.22 Therefore, 
the reduction in the number of osteoclasts observed in the 
present study may be due to pleiotropic effects of statins on the 
osteoclast cells. 
In our study after oral intake of Atorvastatin, the level of 
MDA decreased in rats in the experimental periodontitis 
model. It shows that lipid peroxidation has decreased. These 
results were confirmed by histological observation in which a 
reduction in the inflammation and destruction of the tissue 
was observed. Similar findings have been reported by de 
Araújo Júnior et al.8 
Similar to previous studies, the level of mixed inflamma- 
tion was lower in the Atorvastatin group. Some researchers 
believed that the oral intake of Atorvastatin could reduce the 
cytotoxicity and oxidative stress in experimental periodon- 
titis.12 Nassar et al.11 compared the effect of topical and system- 
atic Atorvastatin and reported the positive effects of both 
treatments on the periodontal tissue of the mouse using 
histomorphometry and immunohistochemistry tests. In the 
current study, both Atorvastatin treatments had decreased the 
inflammation and bone resorption but there were no 
significant differences between the topical injection and oral 
solution groups. Moreover, the dosage used in this study was 
determined based on the previous studies as well as the dura- 
tion of treatment. The malondialdehyde test and histopatho- 
logical study have shown that topical injection of Atorvastatin 
at 0.25 mg/kg dose was as effective as an oral solution at 
12.5 mg/kg in reducing the inflammation and alveolar bone 
resorption in rats which had experimental periodontitis 
induced by ligature threads. The Atorvastatin dosage used in 
the topical treatment was 2% of that used in systemic treat- 
ment. Hence, considering the side effects of this drug in higher 
doses of the solution, the treatment with topical Atorvastatin 
may be the preferred method for this disease. 
However, only in the recent study, the topical effects of 
Atorvastatin have been investigated. Furthermore, not enough 
comparative studies have been performed to investigate the 
difference in the effectiveness of the topical and systematic 
treatment. Therefore, additional experimental laboratory 
studies are needed on this field to find out the best treatment 
doses with the least side effects. 
 
Conclusion 
In this study, both local injection and oral forms of Atorvas- 
tatin decreased inflammation and bone loss in periodontitis. 
No significant difference in their effectiveness was detected. 
However, it seems that local injection is superior to oral form 
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